Abstract

Objective To identify the long-term survival of patients with hepatic carcinoma who received hepatitis B surface antigen (HBsAg) positive donor livers. Method A total of 195 patients were enrolled in the study. They were all diagnosed as having hepatic carcinoma with malignant thrombus in portal vein pre-operation and received liver transplantations between 1999 and 2014. The long-term survival between the patients who received HBsAg positive grafts and those who received HBsAg negative grafts was compared. Result There were no differences in ages, preoperative tumor stages and postoperative mortality between the two groups. There was significant difference in survival time between the two groups (Z=-2.038, P=0.042), with the median survival time of 8.83 months (2.50-24.80 months) in HBsAg positive graft group and 13.12 months (6.50-27.65 months) in HBsAg negative graft group, respectively. The long-term survival rate in HBsAg positive graft group was 48% and that in HBsAg negative graft group was 34.7% (P=0.740, χ2=0.110). However, the proportion of deaths due to recurrence of tumor was high to 75.8% in all causes. Conclusion To prolong the survival time, it is safe and feasible to receive HBsAg positive donor livers in patients with hepatic carcinoma in late stage. However, tumor recurrence was still the main causes of deaths in patients post-operation because of the advanced tumor conditions pre-operation. Key words: Hepatic carcinoma; Liver transplantation; Survival

Full Text

Published Version

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.